片頭痛患者におけるerenumabの有効性と安全性

抄録

Antibody drugs targeting the calcitonin gene–related peptide (CGRP) have recently started appearing in clinical guidelines in the U.S., Europe and Japan as new therapies for the prevention of migraine. In 2021, several CGRP–targeted antibody drugs were approved in Japan, adding to new prophylactic treatment options based on migraine pathophysiology. Erenumab is the first approved human anti–CGRP receptor monoclonal antibody that selectively binds to the CGRP receptor in the world. In 2018, erenumab was launched in the U.S. and Europe for the prevention of migraine. As of May 2021, erenumab had been approved in 71 countries and territories including all EU member states, the U.K., Canada and Australia. In June 2021, erenumab was approved in Japan for use in inhibiting the onset of migraine attacks. In this paper, we draw on the clinical trial data for erenumab in episodic migraine (EM) and chronic migraine (CM) patients to discuss the drug's efficacy and safety in treating migraine, and we describe how erenumab is expected to contribute to improved treatment outcomes in headache patients by targeting the underlying pathophysiology of migraine.